COPD - WHAT FACTORS OF DISEASE DEVELOPMENT STAY IN THE BACKGROUND?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article is dedicated to the chronic obstructive pulmonary disease (COPD), and considers alternative causes of the disease, which can contribute to the onset and development of COPD along with already recognized and proven risk factors. The possible influence of nutritional status and metabolism on the formation of COPD phenotypes is discussed, as evidenced by the results of the presented studies, although the problem has not been sufficiently studied.

Full Text

Restricted Access

About the authors

I. I Baranova

Ural State Medical University; Medical Association “New Hospital"

Email: baranovailona@gmail.com
PhD, Teaching Assistant at the Department of Phthisiology and Pulmonology

I. V Leschenko

Ural State Medical University; Medical Association “New Hospital"

References

  1. Global initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBi/WHO workshop repot Updated 2017. www.goldcopd.com
  2. Lopez-Campos J.L., Ruiz-Ramos M., Soriano J.B. Mortality trends in chronic obstructive pulmonary disease in Europe, 1994-2010: a joinpoint regression analysis. Lance. Respir. Med. 2014;2:54-62. doi: 10.1016/S2213-2600(13)70232-7
  3. Murray C.J., Lopez A.D. Measuring the global burden of disease. N. Engl. J. Med. 2013;369:448-57. doi: 10.1056/NEJMra1201534.
  4. Thun M.J., Carter B.D., Feskanich D., et al. 50-year trends in smoking-related mortality in the United States. N. Engl. J. Med. 2013;368:351-64. doi: 10.1056/NEJMsa1211127.
  5. Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon. Outcomes Res. 2013;5:235-45. Doi: 10.2147/ CEOR.S34321.
  6. Celli B.R., MacNee W., Agusti A., et al.; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004;23:932-46.
  7. Rostron B.L., Chang C.M., Pechacek T.F. Estimation of cigarette smoking attributable morbidity in the United States. JAMA intern. Med. 2014;174:1922-28. doi: 10.1001/jamainternmed.2014.5219.
  8. Barnett K., Mercer S.W., Norbury M., et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37-43. doi: 10.1016/S0140-6736(12)60240-2.
  9. Roche N., Gaillat J., Garre M., et al. Acute respiratory illness as a trigger for detecting chronic bronchitis in adults at risk of COPD: a primary care survey. Prim. Care Respir. J. 2010;19:371-77.
  10. Cote C.G., Casanova C., Mar'in J.M., et al. Validation and comparison of reference equations for the 6-min walk distance test. Eur. Respir. J. 2008;31:571-78. doi: 10.1183/09031936.00104507.
  11. Oga T, Nishimura K., Tsukino M., et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003;167:544-49.
  12. Coxson H.O., Lam S. Quantitative assessment of the airway wall using computed tomography and optical coherence tomography. Proc. Am. Thorac. Soc. 2009;6:439-43. doi: 10.1513/pats.200904-015AW
  13. Coxson H.O., Leipsic J., Parraga G., Sin D.D. Using pulmonary imaging to move COPD beyond FEV1. Am.J. Respir. Crit. Care Med. 2014;190:135-44. doi: 10.1164/rccm.201402-0256PP.
  14. Vanfleteren L.E., Spruit M.A., Groenen M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013;187:728-35. doi: 10.1164/rccm.201209-1665OC.
  15. Burgel P.R., Paillasseur J.L., Peene B., et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS. One. 2012;7:e51048. Doi: W.1371/journaLpone.005W48.
  16. Muscaritoli M., Anker S.D., Argiles J., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases'' and “nutrition in geriatrics''. Clin. Nutr 2010;29:154-59. doi: 10.1016/j.clnu.2009. 12.004.
  17. Berrington de Gonzalez A., Hartge P., Cerhan J.R., et al. Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 2010;363:2211-19. Doi: 10.1056/ NEJMoa1000367.
  18. Whitlock G., tewington S., Sherliker P., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-96. doi: 10.1016/S0140-6736(09)60318-4.
  19. Franciosi L.G., Page C.P., Celli B.R., et al. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir. Res. 2006;7:74. doi: 10.1186/1465-9921-7-74.
  20. Barnes P.J., Chowdhury B., Kharitonov S.A., et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006;174:6-14. doi: 10.1164/rccm.200510-1659PP
  21. Di Stefano A., Capelli A., Lusuardi M., et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. 1998;158:1277-85. Doi: 10.1164/ ajrccm.158.4.9802078.
  22. Gamble E., Grootendorst D.C., Brightling C.E., et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003;168:976-82. Doi: 10.1164/ rccm.200212-14900C.
  23. Hattotuwa K., Gamble E.A., O'Shaughnessy T., et al. Safety of bronchoscopy, biopsy, and BAL in research patients with COPD. Chest. 2002;122: 1909-12.
  24. Culpitt S.V., Rogers D.F., Shah P., et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003;167:24-31. Doi: 10.1164/ rccm.200204-298OC.
  25. Pesci A., Balbi B., Majori M., et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1998;12:380-86. doi: 10.1183/09031936.98.12020380.
  26. Ekberg-Jansson A., Andersson B., Bake B., et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL,CO and to emphysematous changes on high resolution CT. Respir. Med. 2001;95:363-73.
  27. Tsoumakidou M., Tzanakis N., Siafakas N.M. Induced sputum in the investigation of airway inflammation of COPD. Respir. Med. 2003;97:863-71.
  28. Taube C., Holz O., Mucke M., Jorres R.A., Magnussen H. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit.Care Med. 2001;164:1810-15. doi: 10.1164/ajrccm.164.10.2104024.
  29. Kelly M.M., Keatings V, Leigh R., et al. Analysis of fluid-phasemediators.Eur. Respir. J.2002;20(Suppl.37):24 39. doi: 10.1183/09031936.02.00002402
  30. Kharitonov S.A., Barnes P.J. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers. 2002;7:1-32. Doi: 10.1080/ 13547500110104233.
  31. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am. J. Respir. Crit. Care Med. 2005;171:912-30. doi: 10.1164/rccm.200406-710ST.
  32. Bhowmik A., Seemungal T.A., Donaldson G.C., Wedzicha J.A. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur. Respir. J. 2005;26:1009-15. doi: 10.1183/09031936.05.00047305.
  33. Paredi P, Kharitonov S.A., Leak D., et al. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000;162:369-73.
  34. Montuschi P., Barnes P.J. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol. Sci. 2002;23:232-37.
  35. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574 80. doi: 10.1136/thx.2003.019588
  36. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., et al. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta. 2010;1803:3-19. doi: 10.1016/j.bbamcr.2009.07.004.
  37. Klein T., Bischoff R. Physiology and pathophysiology of matrixmetalloproteases. Amino Acids. 2011;41:271-90. doi: 10.1007/s00726-010-0689-x.
  38. Rodriguez D., Morrison C.J., Overall C.M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta. 2010;1803:39-54.
  39. Vanlaere I., Libert C. Matrix metalloproteinases as drug targets ininfections caused by gram-negative bacteria and in septic shock. Clin. Microbiol. Rev. 2009;22:224-39. doi: 10.1128/CMR.00047-08.
  40. Oikonomidi S., Kostikas K., Tsilioni I., et al. Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr. Med. Chem. 2009;16:1214-28.
  41. Baraldo S., Bazzan E., Zanin M.E., et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest. 2007;132:1733-40. doi: 10.1378/chest.06-2819.
  42. Lim S., Roche N., Oliver B.G., et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 2000;162:1355-60.
  43. Churg A., Dai J., Zay K., et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab. Invest. 2001;81:1119-31. doi: 10.1038/labinvest.3780324.
  44. Wagner P.D. Possible mechanisms underlying the development of cachexia in COPD. Eur. Respir. J. 2008;31:492-501. doi: 10.1183/09031936. 00074807.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies